Catalyst Pharmaceuticals, Inc.

NasdaqCM CPRX

Catalyst Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 82.32%

Catalyst Pharmaceuticals, Inc. Gross Profit Margin is 82.32% for the Trailing 12 Months (TTM) ending September 30, 2024, a -4.73% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Catalyst Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 86.41%, a 2.78% change year over year.
Catalyst Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 84.07%, a -1.64% change year over year.
Catalyst Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 85.47%, a -0.60% change year over year.
Catalyst Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 85.98%, a 15.93% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: CPRX

Catalyst Pharmaceuticals, Inc.

CEO	Mr. Richard John Daly M.B.A.
IPO Date	Nov. 8, 2006
Location	United States
Headquarters	355 Alhambra Circle
Employees	167
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Key trends

Past 5 years